CHRS Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Coherus Oncology Inc

Watchlist Manager

Watchlist

Price: 1.145 USD -1.29% Market Closed

Market Cap: $176.6m

	Coherus Oncology Inc NASDAQ:CHRS	US
N	NSK Ltd DUS:NSK	JP

Profitability Summary

Coherus Oncology Inc's profitability score is 10/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

69%

Strong 3Y Average Gross Margin

54%

Gross Margin is Increasing

58% > 69%

Negative Operating Margin

-312%

Negative 3Y Average Operating Margin

-216%

Declining Operating Margin

-86% > -312%

Negative Net Margin

-259%

Strong 3Y Average Net Margin

70%

Declining Net Margin

-103% > -259%

Negative Free Cash Flow Margin

-365%

Negative 3Y Average Free Cash Flow Margin

-134%

Declining Free Cash Flow Margin

-124% > -365%

Negative ROE

-146%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-61%

Declining ROIC

-54% > -134%

View All

Hide

Collapse

10 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.